2026年10月17日-23日，全球医药市场共签署了18项资产授权和合作协议。中国市场共达成3项交易，均为出海交易。
中国市场，本周最大的交易是Gilead Sciences收购瀚辰星泰包括先导候选药物HCXT-2001在内的口服IL-23R抑制剂项目，首付款12.75亿美元。
中国以外市场，本周共签署了15项资产授权和合作协议。最大的交易是Celltrion与Kaigene达成全球独家授权，引进其临床前资产KG013 ，首付款和里程碑合计可达5.805亿美元。
From October 17 to 23, a total of 18 biopharmaceutical licensing and collaboration transactions were announced globally. Of these, 3 were China-related, defined as transactions involving at least one China-based company. All three were out-licensing deals.
In China, the largest transaction was between Gilead Sciences and PeptidStar Therapeutics, for acquiring an oral IL-23R inhibitor program, including lead asset HCXT-2001, with an upfront payment of $1.275 billion.
Outside China, 15 deals were announced. The largest was between Celltrion and Kaigene for a preclinical asset, KG013, worth up to $580.5 million.
3. M&A Deals
4. Top Deals of 2026
